Since its inception in 1983, Virginia Mason Community Clinical Oncology Program (VM-CCOP) has successfully contributed to achieving the overall goal of reducing cancer mortality and morbidity by accruing patients to cancer treatment and cancer control research trials in the communities where the patients live and by facilitating the transference of the state-of-the-art knowledge and technology from the research bases to the communities. During the next five years, the VM-CCOP's specific goals include: (1) Increase accrual to cancer treatment protocols of the Southwest Oncology Group (SWOG) and the Radiation Therapy Oncology Group (RTOG) to exceed 100 clinical credits by 1991; (2) increase accrual to cancer control trials of SWOG, RTOG and M. D. Anderson to exceed 50 credits by 1991; (3) continue to support components and affiliates in metropolitan Seattle and in four smaller Washington state communities; (4) expand the VM-CCOP to include a new major component, Anchorage, Alaska and an affiliate in Fairbanks, Alaska; (5) organize a network of primary care physicians, nurses, and other health care professionals to facilitate cancer control research; (6) continue investigator involvement in protocol development and other research base scientific activities; and (7) evaluate the potential for future cancer control activities with a specific minority population - the Alaskan Natives. The accomplishment of these goals will be facilitated by the VM-CCOPs well established administrative staff, a data management team experienced in high quality data and the administration of a geographically diverse, multi-institutional organization.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035192-09
Application #
3557606
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-01
Project End
1994-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98101
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Groshen, Susan et al. (2015) Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int 116:44-9
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Mata, Douglas A; Groshen, Susan; Von Rundstedt, Friedrich-Carl et al. (2015) Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol 111:923-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 131 publications